Ghent, Belgium

Koen Raemdonck

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 3.1

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2020-2022

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Koen Raemdonck: Innovator in Nanoparticle Technology

Introduction

Koen Raemdonck is a notable inventor based in Ghent, Belgium. He has made significant contributions to the field of micro- and nanoparticles, particularly in the development of innovative compositions for medical applications. With a total of three patents to his name, Raemdonck's work focuses on enhancing the delivery of therapeutic agents.

Latest Patents

One of Raemdonck's latest patents is titled "Particles comprising surfactant protein B and one or more lipids." This invention pertains to coated nanoparticles that utilize surfactant protein B (SP-B) and lipids. The coated particles and their compositions are designed for use as medicaments, particularly in treating various disorders. Another significant patent is "Molecular adjuvants for enhanced cytosolic delivery of active agents." This invention outlines methods and compositions that optimize the intracellular delivery of active agents, especially nucleic acids, enhancing their cytosolic release for therapeutic purposes.

Career Highlights

Raemdonck has worked at prestigious institutions, including Ghent University and Universidad Complutense de Madrid. His research has focused on the intersection of nanotechnology and medicine, leading to advancements in drug delivery systems.

Collaborations

Throughout his career, Raemdonck has collaborated with esteemed colleagues such as Stefaan De Smedt and Kevin Braeckmans. These partnerships have contributed to the success and impact of his research in the scientific community.

Conclusion

Koen Raemdonck is a prominent figure in the field of nanoparticle technology, with a focus on medical applications. His innovative patents and collaborations highlight his commitment to advancing therapeutic delivery systems.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…